Dianthus Therapeutics, Inc. /DE/ Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $58.59 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $52.54, a 138.28% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $22.05, a 21.82% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $18.10.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $23.77, a 13.90% increase from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $20.87, a 72.62% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $12.09.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $10.09, a 13.88% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $58.59 10-Q · filed 2026-08-04 | ||||
| 2026-03-31 | $52.54 10-Q · filed 2026-05-05 | ||||
| 2025-12-31 | $23.77 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $23.45 10-Q · filed 2025-11-05 | ||||
| 2025-06-30 | $21.14 10-Q · filed 2025-08-07 | ||||
| 2025-03-31 | $22.05 10-Q · filed 2025-05-12 | ||||
| 2024-12-31 | $20.87 10-K · filed 2025-03-11 | ||||
| 2024-09-30 | $20.55 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $20.30 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | $18.10 10-Q · filed 2024-05-09 | ||||
| 2023-12-31 | $12.09 10-K · filed 2024-03-21 | ||||
| 2023-09-30 | $12.31 10-Q · filed 2023-11-09 | ||||
| 2022-12-31 | $8.44 8-K · filed 2023-12-21 | $2.13 10-K · filed 2023-03-23 | |||
| 2021-12-31 | $5.92 8-K · filed 2023-12-21 | $9.24 10-K · filed 2022-03-08 | |||
| 2020-12-31 | $10.09 10-K · filed 2021-03-03 | ||||
| 2019-12-31 | $8.86 10-K · filed 2020-03-03 | ||||
| 2018-12-31 | $9.40 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |